These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 34182141)

  • 1. Virus-inspired strategies for cancer therapy.
    Ma XY; Hill BD; Hoang T; Wen F
    Semin Cancer Biol; 2022 Nov; 86(Pt 3):1143-1157. PubMed ID: 34182141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Virotherapy in Germany-Recent Activities in Virus Engineering, Preclinical Development, and Clinical Studies.
    Nettelbeck DM; Leber MF; Altomonte J; Angelova A; Beil J; Berchtold S; Delic M; Eberle J; Ehrhardt A; Engeland CE; Fechner H; Geletneky K; Goepfert K; Holm PS; Kochanek S; Kreppel F; Krutzke L; Kühnel F; Lang KS; Marchini A; Moehler M; Mühlebach MD; Naumann U; Nawroth R; Nüesch J; Rommelaere J; Lauer UM; Ungerechts G
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses.
    Goradel NH; Alizadeh A; Hosseinzadeh S; Taghipour M; Ghesmati Z; Arashkia A; Negahdari B
    Future Oncol; 2022 Jan; 18(2):245-259. PubMed ID: 34821517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Engineering and combining oncolytic measles virus for cancer therapy.
    Leber MF; Neault S; Jirovec E; Barkley R; Said A; Bell JC; Ungerechts G
    Cytokine Growth Factor Rev; 2020 Dec; 56():39-48. PubMed ID: 32718830
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Designer nanocarriers for navigating the systemic delivery of oncolytic viruses.
    Howard F; Muthana M
    Nanomedicine (Lond); 2020 Jan; 15(1):93-110. PubMed ID: 31868115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.
    Tang C; Li L; Mo T; Na J; Qian Z; Fan D; Sun X; Yao M; Pan L; Huang Y; Zhong L
    Clin Transl Oncol; 2022 Sep; 24(9):1682-1701. PubMed ID: 35612653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review.
    Li M; Zhang M; Ye Q; Liu Y; Qian W
    Cancer Biol Med; 2023 Aug; 20(9):646-61. PubMed ID: 37615308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncolytic polio virotherapy of cancer.
    Brown MC; Dobrikova EY; Dobrikov MI; Walton RW; Gemberling SL; Nair SK; Desjardins A; Sampson JH; Friedman HS; Friedman AH; Tyler DS; Bigner DD; Gromeier M
    Cancer; 2014 Nov; 120(21):3277-86. PubMed ID: 24939611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Viro-antibody therapy: engineering oncolytic viruses for genetic delivery of diverse antibody-based biotherapeutics.
    Kontermann RE; Ungerechts G; Nettelbeck DM
    MAbs; 2021; 13(1):1982447. PubMed ID: 34747345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of oncolytic virotherapy: from genetic modification to combination therapy.
    Lan Q; Xia S; Wang Q; Xu W; Huang H; Jiang S; Lu L
    Front Med; 2020 Apr; 14(2):160-184. PubMed ID: 32146606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncolytic Immunotherapy.
    Hennessy ML; Bommareddy PK; Boland G; Kaufman HL
    Surg Oncol Clin N Am; 2019 Jul; 28(3):419-430. PubMed ID: 31079797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.
    Saito K; Shirasawa H; Isegawa N; Shiiba M; Uzawa K; Tanzawa H
    Oral Oncol; 2009 Dec; 45(12):1021-7. PubMed ID: 19833547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Research Advances of Clinical Application of Oncolytic Viruses in Treatment of Gynecologic Cancers.
    Deng M; Wang Q
    Curr Cancer Drug Targets; 2023; 23(7):505-523. PubMed ID: 36824004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncolytic virotherapy: Challenges and solutions.
    Goradel NH; Baker AT; Arashkia A; Ebrahimi N; Ghorghanlu S; Negahdari B
    Curr Probl Cancer; 2021 Feb; 45(1):100639. PubMed ID: 32828575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies.
    Workenhe ST; Mossman KL
    Mol Ther; 2014 Feb; 22(2):251-256. PubMed ID: 24048442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine for advanced cancer immunotherapy.
    Diep YN; Kim TJ; Cho H; Lee LP
    J Control Release; 2022 Nov; 351():1017-1037. PubMed ID: 36220487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The limiting factors of oncolytic virus immunotherapy and the approaches to overcome them.
    Hu PY; Fan XM; Zhang YN; Wang SB; Wan WJ; Pan HY; Mou XZ
    Appl Microbiol Biotechnol; 2020 Oct; 104(19):8231-8242. PubMed ID: 32816087
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus, Oncolytic Virus and Human Prostate Cancer.
    Liu GB; Zhao L; Zhang L; Zhao KN
    Curr Cancer Drug Targets; 2017; 17(6):522-533. PubMed ID: 27993115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The viral approach to breast cancer immunotherapy.
    Arab A; Behravan N; Razazn A; Barati N; Mosaffa F; Nicastro J; Slavcev R; Behravan J
    J Cell Physiol; 2019 Feb; 234(2):1257-1267. PubMed ID: 30146692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncolytic Immunotherapy for Treatment of Cancer.
    Tsun A; Miao XN; Wang CM; Yu DC
    Adv Exp Med Biol; 2016; 909():241-83. PubMed ID: 27240460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.